Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 4Prostatic Neoplasms 3Wilms Tumor 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rectal Neoplasms 2Pulmonary Disease, Chronic Obstructive 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Glioma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Tuberculosis 1Thoracic Cancer 1Shwachman-Diamond Syndrome 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Precancerous Conditions 1Pneumonia 1Pathologic Complete Response 1Pancreatic Intraductal Neoplasms 1Osteosarcoma 1Osteoporosis 1

Interventions

Rituximab 134Cyclophosphamide 126Peripheral Blood Stem Cell Transplantation 74fludarabine phosphate 71Filgrastim 62Etoposide 56Bortezomib 44Vincristine 43Mycophenolic Acid 43Whole-Body Irradiation 42Cytarabine 42Cyclosporine 41Melphalan 38Doxorubicin 37Radiotherapy 36Busulfan 35ibrutinib 34Tacrolimus 34Methotrexate 33Prednisone 32Lenalidomide 30Bendamustine Hydrochloride 30Antilymphocyte Serum 27Dexamethasone 26Carmustine 26Granulocyte Colony-Stimulating Factor 23ibritumomab tiuxetan 20sargramostim 17fludarabine 17Methylprednisolone 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Mantle-Cell × X-Rays × Clear all
NCT00438880 2016-02-04

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
38 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡